...
首页> 外文期刊>Journal of Medicinal Chemistry >Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-(2-(diphenylmethoxy)ethyl)- and 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.
【24h】

Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-(2-(diphenylmethoxy)ethyl)- and 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.

机译:1-(2-(二苯基甲氧基)乙基)-和1-(2-(双(4-(四氟苯基)甲氧基)乙基)-4-(3-苯丙基)新型非哌嗪类似物的设计,合成和生物学评估哌嗪作为多巴胺转运蛋白抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

A series of novel diamine, amine-amide, and piperazinone analogues of N-[2-(bisarylmethoxy)ethyl]-N'-(phenylpropyl)piperazines, GBR 12909 and 12935, were synthesized and evaluated as inhibitors of presynaptic monoamine neurotransmitter transporters. The primary objective of the study was to determine the structural requirements for selectivity of ligand binding and potency for neurotransmitter reuptake inhibition. In general, the target compounds retained transporter affinity; however, structural variations produced significant effects on reuptake inhibition and transporter selectivity. For example, analogues prepared by replacing the piperazine ring in the GBR structure with an N, N'-dimethylpropyldiamine moiety displayed enhanced selectivity for binding and reuptake inhibition at the norepinephrine (NE) transporter site (e.g. 4 and 5). Congeners in which the amide nitrogen atom was attached to the aralkyl moiety of the GBR molecule showed moderate affinity (K(i) = 51-61 nM) and selectivity for the dopamine transporter (DAT) site. In contrast, introduction of a carbonyl group adjacent to either nitrogen atom of the piperazine ring (e.g. 25 and 27) was not well tolerated. From the compounds prepared, analogue 16 was selected for further evaluation. With this congener, locomotor activity induced by cocaine at a dose of 20 mg/kg was attenuated with an AD(50) (dose attenuating cocaine-induced stimulation by 50%) of 60.0 +/- 3.6 mg/kg.
机译:合成了一系列新型的N- [2-(双芳基甲氧基)乙基] -N'-(苯基丙基)哌嗪二胺,胺-酰胺和哌嗪酮类似物GBR 12909和12935,并将其评估为突触前单胺神经递质转运蛋白的抑制剂。该研究的主要目的是确定配体结合的选择性和抑制神经递质再摄取的能力的结构要求。通常,目标化合物保留转运蛋白的亲和力。然而,结构变化对再摄取抑制和转运蛋白选择性产生了显着影响。例如,通过用N,N′-二甲基丙基二胺部分代替GBR结构中的哌嗪环制备的类似物在去甲肾上腺素(NE)转运蛋白位点(例如4和5)显示出增强的结合和再摄取抑制选择性。其中酰胺氮原子连接到GBR分子的芳烷基部分的同类物显示出中等的亲和力(K(i)= 51-61 nM)和对多巴胺转运蛋白(DAT)位点的选择性。相反,与哌嗪环的任一氮原子(例如25和27)相邻的羰基的引入不能很好地耐受。从制备的化合物中,选择类似物16用于进一步评估。使用此同类物,可卡因以20 mg / kg的剂量诱导的运动活性被60.0 +/- 3.6 mg / kg的AD(50)(剂量降低可卡因诱导的刺激剂量的50%)减弱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号